Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

85.78USD
18 Jul 2018
Change (% chg)

$-0.07 (-0.08%)
Prev Close
$85.85
Open
$85.72
Day's High
$86.14
Day's Low
$85.19
Volume
1,784,724
Avg. Vol
2,352,697
52-wk High
$147.13
52-wk Low
$74.14

Select another date:

Tue, Jul 10 2018

BRIEF-Celgene Corp Says Phase III Impassion130 Study Met Co-Primary Endpoint Of Progression-Free Survival

* ANTI-PD-L1 IMMUNOTHERAPY PLUS ABRAXANE® SIGNIFICANTLY REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER IN PHASE III IMPASSION130 STUDY

BRIEF-Evotec And Celgene Enter Into Strategic Oncology Partnership

* DGAP-ADHOC: EVOTEC AND CELGENE ENTER INTO STRATEGIC ONCOLOGY PARTNERSHIP

Celgene profit tops estimates; clarifies path for key MS drug

Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

UPDATE 3-Celgene profit tops estimates; clarifies path for key MS drug

May 4 Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

CORRECTED-UPDATE 2-Celgene tops estimates on higher demand for cancer drug Revlimid

* To resubmit ozanimod marketing application earlier than expected

BRIEF-Celgene Reports Q1 Adjusted Earnings Per Share Of $2.05

* CELGENE REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

Celgene's quarterly profit dips 9 percent

May 4 Celgene Corp's quarterly profit fell about 9 percent despite the U.S. biotech reporting higher revenue, as its expenses surged.

BRIEF-Celgene Corp Entered Into An Amended And Restated Credit Agreement

* CELGENE CORP - ENTERED INTO AN AMENDED AND RESTATED CREDIT AGREEMENT TO EXTEND TERM OF CREDIT FACILITY TO APRIL 25, 2023 FROM APRIL 17, 2022 Source text (https://bit.ly/2HCsgr2) Further company coverage:

BRIEF-Celgene Corp Says CEO Mark Alles's FY 2017 Total Compensation Was $13.1 Mln Vs $12.2 Mln In FY 2016

* CELGENE CORP SAYS CEO MARK ALLES'S FY 2017 TOTAL COMPENSATION WAS $13.1 MILLION VERSUS $12.2 MILLION IN FY 2016 - SEC FILING

BRIEF-Zymeworks And Celgene Expand Bispecific Antibody Collaboration

* ZYMEWORKS AND CELGENE EXPAND BISPECIFIC ANTIBODY COLLABORATION

Select another date: